Jaguar Health (JAGX) Cash & Equivalents (2014 - 2026)

Jaguar Health (JAGX) has reported Cash & Equivalents for 13 consecutive years, with $7.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 27.91% year-over-year to $7.3 million; the TTM figure through Mar 2026 stood at $7.3 million (up 27.91% YoY), while the FY2025 annual figure was $968000.0, down 87.9% from the prior year.
• Cash & Equivalents rose to $7.3 million in Q1 2026 per JAGX's latest filing, from $968000.0 in the prior quarter.
• Across five years, Cash & Equivalents topped out at $17.5 million in Q1 2022 and bottomed at $968000.0 in Q4 2025.
• Historically, Cash & Equivalents has averaged $8.5 million across 5 years, with a median of $8.0 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents jumped 311.31% — and 2025, when it sank 87.9%.
• Jaguar Health's Cash & Equivalents stood at $5.5 million in 2022, then advanced by 18.28% to $6.5 million in 2023, then rose by 23.7% to $8.0 million in 2024, then tumbled by 87.9% to $968000.0 in 2025, then jumped by 651.86% to $7.3 million in 2026.
• Business Quant data shows JAGX's Cash & Equivalents at $7.3 million in Q1 2026, $968000.0 in Q4 2025, and $3.5 million in Q3 2025.